期刊
JOURNAL OF PARKINSONS DISEASE
卷 12, 期 1, 页码 421-436出版社
IOS PRESS
DOI: 10.3233/JPD-212892
关键词
DaTScan; motor; non-motor; Parkinson's disease; sex
资金
- Michael J. Fox Foundation for Parkinson's Research (MJFF)
- Abbvie
- AcureX Therapeutics
- Allergan
- Amathus Therapeutics
- Avid Radiopharmaceuticals
- Bial Biotech
- Biogen
- BioLegend
- Bristol-Myers Squibb
- Calico
- Celgene
- Denali
- 4D pharma pic
- GE Healthcare
- Genetech
- GlaxoSmithKline
- Golub Capital
- Handl Therapeutics
- Insitro
- Janssen
- Lilly
- Lundbeck
- Merck
- Meso Scale Discovery
- Neurocrine Biosciences
- Pfizer
- Piramal
- Prevail Therapeutics
- Roche
- Sanofi Genzyme
- Servier
- Takeda
- Teva
- UCB
- Verily
- Voyager therapeutics
Men with early untreated Parkinson's disease (PD) showed greater longitudinal changes in motor and non-motor features compared to women. They also required higher dopaminergic medication dosages over time. However, there were no sex-related progression patterns observed in biological biomarkers.
Background: Investigation of sex-related motor and non-motor differences and biological markers in Parkinson's disease (PD) may improve precision medicine approach. Objective: To examine sex-related longitudinal changes in motor and non-motor features and biologic biomarkers in early PD. Methods: We compared 5-year longitudinal changes in de novo, untreated PD men and women (at baseline N= 423; 65.5% male) of the Parkinson's Progression Markers Initiative (PPMI), assessing motor and non-motor manifestations of disease; and biologic measures in cerebrospinal fluid (CSF) and dopamine transporter deficit on DaTscan (TM) uptake. Results: Men experienced greater longitudinal decline in self-reported motor (p < 0.001) and non-motor (p = 0.009) aspects of experiences of daily living, such that men had a yearly increase in MDS-UPDRS part II by a multiplicative factor of 1.27 compared to women at 0.7, while men had a yearly increase in MDS-UPDRS part I by a multiplicative factor of 0.98, compared to women at 0.67. Compared to women, men had more longitudinal progression in clinician-assessed motor features in the ON medication state (p = 0.010) and required higher dopaminergic medication dosages over time (p = 0.014). Time to reach specific disease milestones and longitudinal changes in CSF biomarkers and DaTscan TM uptake were not different by sex. Conclusion: Men showed higher self-assessed motor and non-motor burden of disease, with possible contributions from suboptimal dopaminergic therapeutic response in men. However, motor features of disease evaluated with clinician-based scales in the OFF medication state, as well as biological biomarkers do not show specific sex-related progression patterns.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据